Does peritransplantation use of rituximab reduce the risk of EBV reactivation and PTLPD?
Savani
Bipin N
BN
Pohlmann
Paula R
PR
Jagasia
Madan
M
Chinratanalab
Wichai
W
Kassim
Adetola
A
Engelhardt
Brian
B
Greer
John
J
Schuening
Friedrich
F
Goodman
Stacey
S
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D018951:Antigens, CD20 / Q000276:immunology; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D020031:Epstein-Barr Virus Infections / Q000628:therapy / Q000821:virology*; D018380:Hematopoietic Stem Cell Transplantation; D004854:Herpesvirus 4, Human / Q000502:physiology*; D006801:Humans; D008232:Lymphoproliferative Disorders / Q000628:therapy / Q000821:virology*; D000069283:Rituximab; D014184:Transplantation, Homologous; D014775:Virus Activation
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D018951:Antigens, CD20; D000970:Antineoplastic Agents; D000069283:Rituximab